Phase 2 N=29 Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites
Bacterial Infection
Primary: Number of Participants With Adverse Events — 5; 4; 1; 6 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=262 Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization
Osteomyelitis
Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants
Phase 2 N=80 Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis
Osteomyelitis
Primary: Percentage of Participants With Clinical Response at Day 42 in the Clinically Evaluable (CE) Population — 97.0; 87.5; 0.0; 12.5 percentage of participants
Phase 2 N=11 Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children
Hematogenously Acquired Staphylococcus Aureus Osteomyelitis · Bone Infection · Osteomyelitis
Primary: Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to Adverse Events (AEs) — 1 incidence
Phase 2 N=21 Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
Bone Cancer · Chondrosarcoma · Ewing's Sarcoma
Primary: T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects — 7.3; 7.7 milliseconds
Phase 3 N=30 Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections
Refractory Bone or Joint Infections
Primary: Clinical Success at 6 Months — 18; 9; 3 Participants
Phase 2 N=44 Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)
Bone and Joint Infection
Primary: Quantify the Tolerability of Tedizolid for Bone and Joint Infections, Both Hardware and Non-hardware Associated — 0; 0 participants
N/A N=182 Less Infections for the Diabetic Foot
Diabetic Foot
Primary: Number of Participants Experiencing Clinical Failure — 26; 30 Participants
Phase 3 N=149 Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)
Acute Hematogenous Osteomyelitis
Primary: Percentage of Participants With Clinical Improvement in the 3 General Categories of Pain, Inflammation, and Limb Function Based on the Investigator's Overall Assessment…
Phase 2 N=75 Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci
Osteomyelitis
Primary: Any Creatine Phosphokinase (CPK) Elevation > 500 Units Per Liter (U/L) — 4; 5; 2 Participants
N/A N=260 MICRO Study: Detecting Bacterial Infections Related to Orthopaedic Surgical Implants
Open Reduction and Internal Fixation of Extremity Fractures
Primary: Number of Blood Samples With High Levels of Absorbance Via ELISA for Patients (Greater Than 1.5 Ratio Compared to Control Human Serum) — 48; 53 blood draw samples
Phase 4 N=23 Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol
Prosthetic Joint Infection · Vancomycin · Joint Diseases
Primary: Systemic Vancomycin Level - Start of Case — 27.98; 0 ug/mL
Phase 4 N=1,054 Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J)
Bone Infection · Joint Infection
Primary: The Frequency of Definite Failure of Infection Treatment. — 67; 74 Participants
Phase 4 N=14 Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI
Osteonecrosis
Primary: Signal to Noise Ratio (SNR) — 33.82; 129.56 dB — p=0.002
N/A N=225 Incidence and Risk Factors for Surgical Site Infection After Intramedullary Nailing of Femoral and Tibial Fractures
Fracture Fixation, Intramedullary · Surgical Wound Infection
Primary: Incidence of Surgical Site Infection (SSI) Relating to Intramedullary Nailing for Fixation of Diaphyseal Femoral and Tibial Fractures — 26; 195 Participants
Phase 4 N=20 Acute Application of Antibiotic Powder in Open Fracture Wounds
Fractures, Open · Wounds and Injuries--Infections · Anti-Bacterial Agents
Primary: Incidence of Surgical Site Infection During the Post-operative Follow-up Period — 0; 0; 0 participants
N/A N=38 Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections
Musculoskeletal Infection · Acute Hematogenous Osteomyelitis · Septic Arthritis
Primary: Number of Participants With a Pathogen Identified by the Initial Karius Test (IP1) and Standard Culture Methods — 23; 26; 15 Participants
Phase 4 N=160 Antibiotics Usage in Pediatric Orthopaedic Percutaneous Surgery (APOPS)
Supracondylar Humerus Fracture · Post Operative Wound Infection
Primary: Number of Participants With the Presence of Post-Operative Infection — 2; 2 Participants
Phase 2 N=5 ACTIMMUNE in Intermediate Osteopetrosis
Osteopetrosis
Primary: Number of Participants With Treatment Related Adverse Events CTCAE v4.0 Grade 3 or Higher — 0 Participants
N/A N=146 Antibiotic Prophylaxis in Orthopaedic Traumatology
Fractures, Closed · Wounds and Injuries
Primary: Number of Participants With Total Wound Infections — 4; 9 participants — p==0.12
N/A N=142 BBOT: Bacterial Burden in Ortho Trauma Procedures
Orthopaedic Trauma Infections
Primary: Number of Participants With Tissue Samples Identified With Bacterial DNA According to Highly Sensitive Bacterial Assays — 10; 24; 20 Participants
N/A N=52 Osteopathic Otitis Media Research Study
Otitis Media With Effusion
Primary: Change in Middle Ear Effusion Over Four Weeks Following an Episode of Acute Otitis Media — 26; 16; 12; 22 Ears — p=0.02
Phase 3 N=1,061 Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.
Bacterial Infections · Diabetic Foot · Osteomyelitis
Primary: Number of Patients With Clinical Response of Cure Vs. Failure. — 316; 334; 92; 71 patients
Phase 2 N=30 A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 4; 7; 7; 8 Participants
N/A N=22 Prevention of Post Operative Bone Loss in Children
Osteoporosis · Cerebral Palsy · Spina Bifida
Primary: Amount of Bone Density Lost (%) From pre-to Post-operative DXA Scan — 0.043; -0.025 percent change
Phase 3 N=34 Pamidronate to Treat Osteogenesis Imperfecta in Children
Osteogenesis Imperfecta
Primary: Change in Bone Mineral Density in Response to Pamidronate — -3.54; -4.98 Z-score
N/A N=63 Comparing Synthetic Bone Alone Versus Synthetic Bone With Bone Marrow in Bone Lesions
Bone Diseases
Primary: Resorption of Graft Material (GR) Compared at 24 Months — 51; 47 percentage of resorption — p=<0.01
Phase 2 N=15 Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation
Prosthetic Joint Infection
Primary: Safety Evaluations: Number and Frequency of Adverse Events Among Participants — 14; 14; 14; 14 Participants
N/A N=127 Continuous Intraosseous Vascular Access Over 48 Hours
Intraosseous Vascular Access
Primary: Serious Complications From Intraosseous (IO) Access — 0; 0; 0; 0 Participants
Phase 1 N=6 Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA)
Peripheral Artery Disease · Vascular Disease · Critical Limb Ischemia
Primary: Number of Participants With Treatment-related Adverse Events Occurring During the Enrollment Period as Assessed by the Investigator Using the CTCAE 4.0 Scale. — 2; 0…